metformin has been researched along with Bile Duct Obstruction, Intrahepatic in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both metformin-treated wild-type C57 mice and hepatic SIRT1-mutant mice had increased hepatic and serum bile acid levels." | 1.46 | Metformin impairs systemic bile acid homeostasis through regulating SIRT1 protein levels. ( Chang, Y; Chen, Q; Cui, X; Fang, F; Kong, X; Yang, J; Yang, X; Yao, L; Zhang, H; Zou, Y, 2017) |
| "In her fifth pregnancy, treatment for gestational diabetes mellitus with metformin was associated with a lowering effect on bile acids and liver enzymes, indicating a possible role for metformin in the management of obstetric cholestasis." | 1.43 | Managing Recurring Obstetric Cholestasis With Metformin. ( Ali, A; Elfituri, A; Shehata, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lien, F | 1 |
| Berthier, A | 1 |
| Bouchaert, E | 1 |
| Gheeraert, C | 1 |
| Alexandre, J | 1 |
| Porez, G | 1 |
| Prawitt, J | 1 |
| Dehondt, H | 1 |
| Ploton, M | 1 |
| Colin, S | 1 |
| Lucas, A | 1 |
| Patrice, A | 1 |
| Pattou, F | 1 |
| Diemer, H | 1 |
| Van Dorsselaer, A | 1 |
| Rachez, C | 1 |
| Kamilic, J | 1 |
| Groen, AK | 1 |
| Staels, B | 1 |
| Lefebvre, P | 1 |
| Chen, Q | 1 |
| Yang, X | 1 |
| Zhang, H | 1 |
| Kong, X | 1 |
| Yao, L | 1 |
| Cui, X | 1 |
| Zou, Y | 1 |
| Fang, F | 1 |
| Yang, J | 1 |
| Chang, Y | 1 |
| Elfituri, A | 1 |
| Ali, A | 1 |
| Shehata, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of the Glycemic and Ponderal Status on Tissues Gene Expression (Biological Tissue Collection)[NCT01129297] | 20,000 participants (Anticipated) | Observational | 2006-06-13 | Recruiting | |||
| METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study[NCT03056274] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for metformin and Bile Duct Obstruction, Intrahepatic
| Article | Year |
|---|---|
Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk.
Topics: Adenylate Kinase; Amino Acid Sequence; Aminoimidazole Carboxamide; Animals; Bile Acids and Salts; Bi | 2014 |
Metformin impairs systemic bile acid homeostasis through regulating SIRT1 protein levels.
Topics: Acetylation; Animals; Bile Acids and Salts; Cholestasis, Intrahepatic; Gene Expression Regulation; H | 2017 |
Managing Recurring Obstetric Cholestasis With Metformin.
Topics: Adult; Bile Acids and Salts; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Diabetes, Gesta | 2016 |